Membrane estrogen receptor alpha (ERα) participates in flow-mediated dilation in a ligand-independent manner

  1. Julie Favre
  2. Emilie Vessieres
  3. Anne-Laure Guihot
  4. Coralyne Proux
  5. Linda Grimaud
  6. Jordan Rivron
  7. Manuela CL Garcia
  8. Léa Réthoré
  9. Rana Zahreddine
  10. Morgane Davezac
  11. Chanaelle Fébrissy
  12. Marine Adlanmerini
  13. Laurent Loufrani
  14. Vincent Procaccio
  15. Jean-Marie Foidart
  16. Gilles M Flouriot
  17. Francoise Lenfant
  18. Coralie Fontaine
  19. Jean-Françoise Arnal
  20. Daniel Henrion  Is a corresponding author
  1. Université d'Angers, France
  2. INSERM U1048, Paul Sabatier University (Toulouse III), France
  3. Université de Liège, Belgium
  4. INSERM U1085, IRSET (Institut de Recherche en Santé, Environnement et Travail), France

Abstract

Estrogen receptor alpha (ERα) activation by estrogens prevents atheroma through its nuclear action whereas plasma membrane-located ERα accelerates endothelial healing. The genetic deficiency of ERα was associated with a reduction in flow-mediated dilation (FMD) in one man. Here, we evaluated ex vivo the role of ERα on FMD of resistance arteries. FMD, but not agonist (acetylcholine, insulin)-mediated dilation, was reduced in male and female mice lacking ERα (Esr1-/- mice) compared to wild-type mice and was not dependent on the presence of estrogens. In C451A-ERα mice lacking membrane ERα, not in mice lacking AF2-dependent nuclear ERα actions, FMD was reduced, and restored by antioxidant treatments. Compared to wild-type mice, isolated perfused kidneys of C451A-ERα mice revealed a decreased flow-mediated nitrate production and an increased H2O2 production. Thus, endothelial membrane ERα promotes NO bioavailability through inhibition of oxidative stress and thereby participates in FMD in a ligand-independent manner.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files are provided for each figure and supplement

Article and author information

Author details

  1. Julie Favre

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Emilie Vessieres

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Anne-Laure Guihot

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Coralyne Proux

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Linda Grimaud

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Jordan Rivron

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Manuela CL Garcia

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Léa Réthoré

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Rana Zahreddine

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Morgane Davezac

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Chanaelle Fébrissy

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Marine Adlanmerini

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Laurent Loufrani

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3397-2335
  14. Vincent Procaccio

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Jean-Marie Foidart

    Groupe Interdisciplinaire de Génoprotéomique Appliquée, Université de Liège, Liège, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  16. Gilles M Flouriot

    INSERM U1085, IRSET (Institut de Recherche en Santé, Environnement et Travail), Rennes, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Francoise Lenfant

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  18. Coralie Fontaine

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  19. Jean-Françoise Arnal

    Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), INSERM U1048, Paul Sabatier University (Toulouse III), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  20. Daniel Henrion

    MITOVASC, CNRS UMR 6015, INSERM U1083, Université d'Angers, Angers, France
    For correspondence
    daniel.henrion@univ-angers.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1094-0285

Funding

Fondation pour la Recherche Médicale (FRM - DPC20171138957)

  • Daniel Henrion

Fondation pour la Recherche Médicale (Equipe FRM DEQ20160334924)

  • Jean-Françoise Arnal

Agence Nationale de la Recherche (ANR-18-CE14-0016-01)

  • Daniel Henrion

Fondation Lefoulon Delalande (N/A)

  • Julie Favre

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The investigation was conducted in accordance with the guidelines from Directive 2010/63/EU of the European Parliament for the protection of animals used for scientific purposes (authoriza-tion of the laboratory: # 00577). The protocol was approved by the Institutional Animal Care and Use Committee (IACUC): Committee on the Ethics of Animal Experiments (CEAA) of "Pays de la Loire" (permits #14335, #16740, and #16108).The mice were anesthetized with isoflurane (2.5%) and euthanized using a CO2 chamber and every effort was made to minimize suffering.

Copyright

© 2021, Favre et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,166
    views
  • 152
    downloads
  • 16
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Julie Favre
  2. Emilie Vessieres
  3. Anne-Laure Guihot
  4. Coralyne Proux
  5. Linda Grimaud
  6. Jordan Rivron
  7. Manuela CL Garcia
  8. Léa Réthoré
  9. Rana Zahreddine
  10. Morgane Davezac
  11. Chanaelle Fébrissy
  12. Marine Adlanmerini
  13. Laurent Loufrani
  14. Vincent Procaccio
  15. Jean-Marie Foidart
  16. Gilles M Flouriot
  17. Francoise Lenfant
  18. Coralie Fontaine
  19. Jean-Françoise Arnal
  20. Daniel Henrion
(2021)
Membrane estrogen receptor alpha (ERα) participates in flow-mediated dilation in a ligand-independent manner
eLife 10:e68695.
https://doi.org/10.7554/eLife.68695

Share this article

https://doi.org/10.7554/eLife.68695

Further reading

    1. Cell Biology
    Tomoharu Kanie, Roy Ng ... Peter K Jackson
    Research Article

    The primary cilium is a microtubule-based organelle that cycles through assembly and disassembly. In many cell types, formation of the cilium is initiated by recruitment of ciliary vesicles to the distal appendage of the mother centriole. However, the distal appendage mechanism that directly captures ciliary vesicles is yet to be identified. In an accompanying paper, we show that the distal appendage protein, CEP89, is important for the ciliary vesicle recruitment, but not for other steps of cilium formation (Tomoharu Kanie, Love, Fisher, Gustavsson, & Jackson, 2023). The lack of a membrane binding motif in CEP89 suggests that it may indirectly recruit ciliary vesicles via another binding partner. Here, we identify Neuronal Calcium Sensor-1 (NCS1) as a stoichiometric interactor of CEP89. NCS1 localizes to the position between CEP89 and a ciliary vesicle marker, RAB34, at the distal appendage. This localization was completely abolished in CEP89 knockouts, suggesting that CEP89 recruits NCS1 to the distal appendage. Similarly to CEP89 knockouts, ciliary vesicle recruitment as well as subsequent cilium formation was perturbed in NCS1 knockout cells. The ability of NCS1 to recruit the ciliary vesicle is dependent on its myristoylation motif and NCS1 knockout cells expressing a myristoylation defective mutant failed to rescue the vesicle recruitment defect despite localizing properly to the centriole. In sum, our analysis reveals the first known mechanism for how the distal appendage recruits the ciliary vesicles.

    1. Cell Biology
    Ling Cheng, Ian Meliala ... Mikael Björklund
    Research Article

    Mitochondrial dysfunction is involved in numerous diseases and the aging process. The integrated stress response (ISR) serves as a critical adaptation mechanism to a variety of stresses, including those originating from mitochondria. By utilizing mass spectrometry-based cellular thermal shift assay (MS-CETSA), we uncovered that phosphatidylethanolamine-binding protein 1 (PEBP1), also known as Raf kinase inhibitory protein (RKIP), is thermally stabilized by stresses which induce mitochondrial ISR. Depletion of PEBP1 impaired mitochondrial ISR activation by reducing eukaryotic translation initiation factor 2α (eIF2α) phosphorylation and subsequent ISR gene expression, which was independent of PEBP1’s role in inhibiting the RAF/MEK/ERK pathway. Consistently, overexpression of PEBP1 potentiated ISR activation by heme-regulated inhibitor (HRI) kinase, the principal eIF2α kinase in the mitochondrial ISR pathway. Real-time interaction analysis using luminescence complementation in live cells revealed an interaction between PEBP1 and eIF2α, which was disrupted by eIF2α S51 phosphorylation. These findings suggest a role for PEBP1 in amplifying mitochondrial stress signals, thereby facilitating an effective cellular response to mitochondrial dysfunction. Therefore, PEBP1 may be a potential therapeutic target for diseases associated with mitochondrial dysfunction.